Catalog No.
Product Name
Application
Product Information
Product Citation
-
GPR3 agonist/NOS/ NADPH oxidases inhibitor
Diphenyleneiodonium chloride has been shown to be a potent irreversible inhibitor of NOS2 (iNOS) from macrophages and NOS3 (eNOS) from endothelial cells. -
GPR40/FFA1 agonist
AMG-837 calcium hydrate is a potent, orally bioavailable GPR40 agonist. -
FFA4/GPR120 agonist
GSK137647A is a selective FFA4 agonist, with pEC50 of 6.3, 6.2, and 6.1 for human, Mouse and Rat FFA4, respectively. - Deoxycholic acid, extracted from Pig bile, Suitability:Ethanol,ether,three oxygen methane,acetone,acetic acid,alkali hydroxide and alkali carbonate solution.
- GPR120 modulator 1 is useful for modulating G protein-coupled receptor 120 (GPR120).
- GPR120 modulator 2 is useful for modulating G protein-coupled receptor 120 (GPR120).
-
GPR139 agonist
JNJ 63533054 is a potent and selective GPR139 agonist with EC50 value of 16nm. -
GPR119 agonist
APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119. - Versipelostatin is a novel GRP78/Bip molecular chaperone down-regulator of microbial origin that was isolated from the metabolite of Streptomyces versipellis strain 4083-SVS6.
-
GPR139 antagonist
NCRW0005-F05, first antagonist selective for GPR139 (IC50 value 0.21 uM); a useful tool to study GPR139 pharmacology, especially in combination with the GPR139 agonist JNJ 63533054. -
GPR39 agonist
TC-G-1008 is a GPR39 (zinc receptor) agonist (EC50 values are 0.4 and 0.8 nM for rat and human receptors respectively).- Urszula Doboszewska, .et al. , Cell Mol Life Sci, 2023, Apr 25;80(5):133 PMID: 37185787
- Urszula Doboszewska, .et al. , Cells, 2023, Jan 9;12(2):264 PMID: 36672199
-
hGPR91 antagonist
HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC50 of 7 μM. -
GPR40 full agonist
GPR40 agonist 1 is a potent and novel GPR40 full agonist with an EC50 of 2 nM and 17 nM for hGPR40 and rGPR40, respectively. -
GPR4 antagonist
NE 52-QQ57 is a selective, and orally available GPR4 antagonist with an IC50 of 70 nM. Anti-inflammatory activities. -
GPR120 agonist
GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209. -
GPR119 agonist
Firuglipel (DS-8500a) is an orally available, potent and selective GPR119 agonist. -
GPR120 agonist
GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate. -
brain-penetrant GPR88 agonist
RTI-13951-33 is a potent, selective, and brain-penetrant GPR88 agonist, with an EC50 of 25 nM in GPR88 cAMP functional assay. -
GPR40/FFAR1 agonist
GPR40/FFAR1 modulator 1 is an agonist and an allosteric modulator for Gq-coupled free fatty acid receptor 1 (GPR40/FFAR1). -
Gpr120 agonist
GPR120-IN-1 is a selective Gpr120 agonist with a logEC50 of ?7.62. -
GPR40 agonist
Setogepram sodium salt (PBI-4050 sodium salt) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. -
GPR109A agonist
Monomethyl fumarate, an active metabolite of Dimethyl fumarate (DMF), is a potent GPR109A agonist. Monomethyl fumarate has the potential for multiple neuroprotective pathways and other models of retinal disease.
